Human 2D neural-network models
Patient-derived cells are grown into living human brain networks on a dish, a faithful, scalable window into real disease biology.
Neuroscience drug discovery
Reversing
Cognitive Decline
Unlocking novel neuroscience therapeutics with an AI-assisted target discovery platform built on the brain's own neural networks.
- 3
- Disease network signatures mapped
- 4+
- Programs from one unified insight
- >$1T
- Annual U.S. cost we're taking on
The opportunity
Cognitive disorders cost the U.S. over a trillion dollars a year.
An aging population faces an accelerating wave of cognitive decline. Tens of millions of people live with conditions that today's medicines manage but do not cure.
7M
Living with dementia
$592B annual U.S. cost
8M
Living with bipolar disorder
$220B annual U.S. cost
3.7M
Living with schizophrenia
$280B annual U.S. cost
For decades, neurological drug discovery has been built on flawed assumptions. Hundreds of failed clinical trials and billions in wasted funding point to the same conclusion: the field needs new targets, and a fundamentally better way to find them.
The science
A new approach to an old problem.
Healthy cognition depends on properly formed, properly communicating neural networks. The tiny connection points between neurons, the dendritic spines, are disrupted early and consistently across Alzheimer's disease, bipolar disorder, schizophrenia, and other neurological conditions.
Domina was founded on a single insight: these disorders share a common underlying mechanism. By targeting this early, functional read-out, we aim to restore healthy neural function rather than simply mask its absence.
Recent validation of neural-network dysregulation well ahead of symptom onset gives us a foundation the field did not have even five years ago. The window to get ahead of this crisis is open, and Domina is built to move through it.
The platform
Our secret sauce: 2D neural networks.
At the heart of Domina is a patentable, AI-assisted target discovery platform. We grow human brain neural-network models from patient cells, then use machine learning to read their communication signatures and find compounds that restore healthy function.
Map network communication
Machine learning reads how each network signals and where diseased networks diverge from healthy ones.
Identify novel targets
Distinct disease signatures reveal upstream targets that shape neural-network formation, mechanisms the industry has not yet explored.
Find and validate compounds
We screen for compounds that renormalize network function, then validate the strongest hits as potential first-in-class therapeutics.
Clear path to IP
First-in-class compounds targeting novel mechanisms across a pipeline of cognitive disorders.
The pipeline
Multiple programs from one unified insight.
A single biological idea, restoring neural-network function reverses cognitive decline, generates therapeutic programs across many cognitive disorders. Our most advanced work is anchored in Alzheimer's disease and bipolar disorder.
Alzheimer's disease
Lead-stage
Schizophrenia
Target ID
Bipolar disorder
Proof of concept
Parkinson's disease
Signature mapped
Mapping pipeline
The team
Led by experienced biotech professionals and industry experts.
Deep expertise across bioinformatics, medicinal chemistry, neuroscience, and stem cell biology.
Ravi Jain, PhD
Co-Founder & CEO
25+ years in bioinformatics and genomics; repeat biotech founder.
Warren Wade, PhD
VP of Discovery
35+ years in medicinal chemistry and neurological drug discovery.
Kumar Hari, PhD
VP of Biology
25+ years in cell biology and diagnostics; assay development and MOA elucidation.
Evan Snyder, MD PhD
Co-Founder & SAB
Director, Center for Stem Cells & Regenerative Medicine, Sanford Burnham Prebys.
Petr Sramek
Board of Directors
Managing Partner, LongevityTech.fund.
Bill Keating
Board of Directors
Managing Partner, Inflection Point Bio.
Get in touch
Let's talk.
For scientific, partnering, or general inquiries, send us a note using the form. We read everything.